Topics

RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2

22:56 EST 15 Jan 2020 | RTTNews

Shares of RAPT Therapeutics Inc. (RAPT) have gained nearly 29 percent over the last five trading days as the Company gears up for some near-term clinical milestones.

Original Article: RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2

NEXT ARTICLE

More From BioPortfolio on "RAPT Therapeutics Gains 29% In 5 Days, FLX475 Phase 2 Data Due In Q2"

Quick Search